Research  >  Research  >  Centres  >  HOPE Research Centre  >  Publications  >  Peer-reviewed publications

Peer-reviewed publications

  1. Seung SJ, Saherawala H, Nguyen L, Gatley JM, Liu N, Kebabdjian M, Earle C, Klotz L, Mittmann N. Hospital Encounters and Associated Costs of the Prostate Evaluation for Clinically Important Disease: MRI vs Standard Evaluation Procedures (PRECISE) Study from a Provincial-Payer Perspective. Canadian Urologic Association Journal. Accepted February 2023.
  2. Moldaver DM, Hassan S, Seung SJ, Edwin J, Clouthier DL, Vera-Badillo FE. A real-world retrospective analysis of the management of metastatic castrate-resistant prostate cancer in Ontario, Canada from 2010 - 2018. Urologic Oncology. In Press 2023 Jan. (10.1016/j.urolonc.2022.11.019).
  3. Mittmann N, Seung SJ, Diong C, Gatley JM, Wolfson M, Guertin MH, Pashayan N, Simard J, Chiarelli AM. Using Real-World Data to Determine Health System Costs of Ontario Women Screened for Breast Cancer. Current Oncology. 2022 October; 29: 8330–8339. (10.3390/curroncol29110657).
  4. Hurry M, Hassan S, Seung, SJ, Walton RN, Elnoursi A, McGee J. Real World Treatment Patterns, Survival and Costs for Ovarian Cancer in Canada: A Retrospective Cohort Study Using Provincial Administrative Data. Journal of Health Economics and Outcomes Research. 2021 Dec; 8(2): 114-121. (10.36469/jheor.2021.29145).
  5. Seung SJ, Hurry M, Hassan S, Elnoursi A, Scheider KAB, Wagner D, Edwin JJ, Aw ATW. Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario. Current Oncology. 2021 Nov; 28(6): 4832-4844. (10.3390/curroncol28060408).
  6. Pope JE, Quansah K, Hassan S, Seung SJ, Flavin J, Kolb M. Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years. Journal of Rheumatology. 2021 Sept; 48(9): 1427-1434 (10.3899/jrheum.201049).
  7. Seung SJ, Hurry M, Walton RN, Evans WK. Retrospective cohort study of unresectable stage III non-small cell lung cancer in Canada. Current Oncology. 2020 Aug;27(4): e354-e360.
  8. Seung SJ, Hurry M, Walton RN, Evans WK. Real world treatment patterns and survival of stage IV non-small cell lung cancer in Canada. Current Oncology. 2020 Aug; 27(4): e361–e367.
  9. Seung SJ, Traore AN, Pourmirza B, Fathers KE, Coombes M, Jerzak KJ. A population-based analysis of breast cancer incidence and survival by subtype in Ontario women. Current Oncology. 2020 Apr; 27(2): e191–e198.
  10. Hassan S, Seung SJ, Clark R, Gibbs JC, McArthur C, Mittmann N, Thabane L, Kendler D, Papaioannou A, Wark JD, Ashe MC, Adachi JD, Templeton JA, Giangregorio LM. Describing the resource utilization and costs associated with vertebral fractures: The Build Better Bones with Exercise (B3E) Pilot Trial". Osteoporosis International.2020 Mar 26; 1-9 (10.1007/s00198-020-05387-z).
  11. Look Hong NJ, Liu N, Wright FC, MacKinnon M, Seung SJ, Earle CC, Gradin S, Sati S, Buchman S, Mittmann N. Assessing the impact of early identification of patients appropriate for palliative care on resource utilization and costs in the final month of life. JCO Oncology Practice.2020 Mar 20; (1200/JOP.19.00397).
  12. Mittmann N, Liu N, Cheng SY, Seung SJ, Saxena FE, Look Hong NJ, Earle CC, Cheung M, Leighl N, Coburn N, DeAngelis C, Evans WK. Health system costs for cancer medications and radiation treatment in the four most common cancers. CMAJ Open. 2020 Mar 16; 8(1): E191-198 (9778/cmajo.20190114).
  13. Mittmann N, Liu N, MacKinnon M, Seung SJ, Look Hong NJ, Earle CC, Gradin S, Sati S, Buchman S, Jakda A, Wright FC. Does early palliative identification improve the use of palliative care services? PLOS ONE.2020 Jan 31; 15(1): e0226597 (1371/journal.pone.0226597).
  14. Mittmann N, Cheng SY, Liu N, Seung SJ, Saxena FE, DeAngelis C, Look Hong NJ, Earle CC, Cheung M, Leighl N, Coburn N, Evans WK. The generation of two specific cancer costing algorithms using Ontario administrative databases. Current Oncology. 2019 Oct; 26(5): e682-e692 (10.3747/co.26.5279).
  15. SY Cheng, Saxena FE, Seung SJ, Earle CC, Chan K, Mittmann N. Demographic characteristics and cost of treatment among oncology patients in a publicly funded system, the Ontario Trillium Drug Program: a retrospective cohort study. CMAJ Open2019 Aug 20; 7(3): E516-E523.
  16. Seung SJ, Hurry M, Hassan S, Walton RN, Evans WE. Cost of illness study for non-small cell lung cancer using real-world data. Current Oncology2019 Apr; 26(2): 102-107.
  17. Mittmann N, Beglaryan H, Liu N, Seung SJ, Rahman F, Gilbert J, De Rossi S, Earle CC, Grunfeld E, Zwicker V, LeBlanc D, Sussman J. Examination of health system resources and costs association with transitioning cancer survivors to primary care: a propensity-score-matched cohort study. Journal of Oncology Practice.2018 Nov 1;14(11): e653-e664.
  18. Mittmann N, Earle CC, Cheng SY, Julian JA, Rahman F, Seung SJ, Levine MN. Population-based study to determine the health system costs of using the 21-gene assay. Journal of Clinical Oncology2018 Jan 20; 36(3): 238-243.
  19. Gwadry-Sridhar F, Nikan S, Hamou A, Seung SJ, Petrella T, Joshua AM, Ernst S, Mittmann N. Resource utilization and costs of managing patients with advanced melanoma: a Canadian population-based study. Current Oncology.2017 Jun; 24(3): 168-175.
  20. Hassan S,Seung SJ,Cheung MC, Fraser G, Kuriakose B, Trambitas C, Mittmann N. Examining the medical resource utilization and costs of relapsed and refractory chronic lymphocytic leukemia in Ontario. Current Oncology.2017 Feb; 24(1): e50-e54.
  21. Naik H, Howell D, Su J, Qiu X, Brown MC, Vennettilli A, Irwin M, Pat V, Solomon H, Wang T, Hon H, Eng L, Mahler M Thai H, Ho V, Xu W, Seung SJ, Mittmann N. EQ-5D Health Utility Scores: Data from a Comprehensive Canadian Cancer Centre. Patient. 2017 Feb; 10(1): 105-115.
  22. Naik H, Qui X, Brown M C, Mahler M, Ho H, Tiessen K, Thai H, Ho V, Gonos C, Charow R, Pat V, Irwin M, Herzog L, Ho A, Xu W, Howell D, Seung SJ, Liu G, Mittmann N. Cancer patients’ willingness to routinely complete the EQ-5D instrument at clinic visits. Journal of Population Therapeutics and Clinical Pharmacology. 2016 Sep 13; 23(3): e196-e204.
  23. Rahman F, Seung SJ, Cheng SY, Saherawala H, Earle CC, Mittmann N. Radiation costing methodologies: a systematic review. Current Oncology. 2016 Aug; 23(4): e392-e408.
  24. Liu N, Mittmann N, Coyte PC, Hancock-Howard R, Seung SJ, Earle C. Phase-specific health care costs of cervical cancer: estimates from a population-based study. American Journal of Obstetrics & Gynecology. 2016 May; 214(5): e1-615.
  25. Raju RS, Coburn N, Liu N, Porter JM, Seung SJ, Cheung MC, Leighl NB, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earl CC, Mittmann N. A population-based study of the epidemiology of pancreatic cancer: A brief report. Current Oncology. 2015 Dec; 22(6): e478-84.
  26. Cheung MC, Earle CC, Ho TH, Rangrej J, Liu N, Barbera L, Saskin R, Porter J, Seung SJ, Mittmann N. The impact of aggressive management and palliative care on end-of-life costs. 2015 Sep 15; 121(18): 3307-15.
  27. Heelan K, Hassan S, Bannon G, Knowles SR, Walsh S, Shear NH, Mittmann N. Cost and resource use of pemphigus and pemphigoid disorders pre- and post rituximab. Journal of Cutaneous Medicine and Surgery. 2015 May-Jun; 19(3): 274-82.
  28. Cheung MC, Hay AE, Crump M, Imrie KR, Song Y, Hassan S, Risebrough N, Sussman J, Couban S, MacDonald D, Kukreti V, Kouroukis CT, Baetz T, Szwajcer P, Shepherd L, Meyer RM, Le, A, Chen BE, Mittmann N, Committee on Economic Analysis and the Hematology Disease Site Committee, NCIC Clinical Trials Group. Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12 Journal of National Cancer Institute. 2015 Apr 13; 107(7) pii (10.1093/JNCI/djv106).
  29. Tseng E, Prica A, Zhung L, Mittmann N, Seung SJ, Callum J, Wells RA, Kim T, Buckstein R. Monthly blood transfusions decrease after four months of azacitidine. Vox Sanguinis. 2015 Aug;109(2):163-167.
  30. Mittmann N, Seung SJ, Liu N, Porter J, Leighl N, Trudeau M, Evans WK, Earle CC. Home care utilization and costs in stage IV lung cancer: a Canadian public payer experience. Lung Cancer Management. Published Online: 2014 Dec 22.
  31. Mittmann N, Porter NJ, Rangrej J, Seung SJ, Liu N, Saskin R, Cheung MC, Leighl NB, Hoch JS, Trudeau M, Evans WK, Dainty KN, DeAngelis C, Earle CC. Health system costs for stage-specific breast cancer: a population based approach. Current Oncology.2014 Dec; 21(6): 281-93.
  32. Mittmann N, Seung SJ, Liu N, Porter J, Saskin R, Hoch JS, Evans WK, Leighl NB, Trudeau M, Earle CC. Population based utilization of radiation therapy by a Canadian breast cancer cohort. Current Oncology.2014 Oct; 21(5): e715-7.
  33. Mittmann N, Liu N, Porter JM, Isogai PK, Seung SJ, Saskin R, Cheung MC, Leighl NB, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earle CC. Homecare utilization and costs in colorectal cancer by stage of disease. CMAJ Open.2014 Feb 4; 2(1): E11-7.
  34. Chan BC, Seung SJ, McLean D, Bell H, Bell M, Shear NH, Mittmann N. Etanercept patient assistance program: another data source for epidemiological studies? Advances in Pharmacoepidemiology and Drug Safety.2013 Apr 29; 2(2):132 (10.4172/2167-1052.1000132).
  35. Tam VC, Ko YJ, Mittmann N, Cheung MC, Kumar K, Hassan S, Chan KK. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Current Oncology. 2013; 20(2): e90-e106.
  36. Mittmann N, Seung SJ, Hill MD, Phillips SJ, Hachinski V, Coté R, Buck BH, Mackey A, Gladstone DJ, Howse DC, Shuaib A, Sharma M. Impact of disability status on ischemic stroke costs in Canada in the first year. Canadian Journal of Neurological Sciences.2012 Nov; 39(6): 793-800.
  37. Mittmann N, Seung SJ. Rash Rates with EGFR Inhibitors: Meta-analysis.Current Oncology. 2011 Apr; 18(2). Epublication e54-63.
  38. Valgimigli M, Mittmann N, Cohen D J, Campo G, Isogai P K, Seung SJ, Dulisse B, Arcozzi C, Squasi P, Percoco G, Ferrari R. A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. International Journal of Cardiology.2008 Aug 1; 128(1): 53-61.
  39. Mittmann N, Seung SJ, Pisterzi L, Michaels D. Nursing workload associated with hospital patient care. Disease Management and Health Outcomes. 2008; 16(1): 53-61.
  40. Lamers LM, Al MJ, vanden Bent MJ, Stupp R, Gorlia T, Crott R, Mittmann N, Seung SJ, Wasserfallen JB, Uyl-de Groot CA. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: report from the EORTC 26981/22981 NCI-C CE3 intergroup study. 2008 Mar 15;112(6): 1337-44.
  41. Mittmann N¸ FitzGerald JM, Kuramoto L, Seung SJ, Haddon J, Bradley-Kennedy C. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respiratory Medicine 2008; 102 (3): 413-21.
  42. Seung SJ, Mittmann N. Urgent care costs of uncontrolled asthma in Canada, 2004. Canadian Respiratory Journal.2005 Nov-Dec. 12 (8): 435-6.
  43. Oh PI, Cohen EA, Mittmann N, Seung SJ. The economics of adjunctive therapies in coronary angioplasty: drugs, devices or both? Canadian Journal of Clinical Pharmacology. 2004 Fall; 11(2): e202-e211.
  44. Mittmann N, Knowles SR, Seung SJ, Cornish W, Oh PI, Paton T. The impact of medicinal marijuana use on the Canadian medical community. Canadian Journal of Hospital Pharmacy. 2004 Jun; 57(3): 65-72.